NOVOSIMILAR Trademark

Trademark Overview

On Monday, July 23, 2018, a trademark application was filed for NOVOSIMILAR with the United States Patent and Trademark Office. The USPTO has given the NOVOSIMILAR trademark a serial number of 88048619. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, June 10, 2019. This trademark is owned by Agenus Inc.. The NOVOSIMILAR trademark is filed in the Pharmaceutical Products category with the following description:

cells for medical or clinical use; pharmaceuticals, medicines, biologics, biotherapeutics, therapeutics, and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejection, inflammatory diseases, and life-threatening diseases; pharmaceutical and biopharmaceutical preparations for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejection, inflammatory diseases, and life-threatening diseases; pharmaceutical, medical, scientific, and biopharmaceutical research and development; and scientific research in the fields of immunopharmaceuticals, vaccines, pharmaceuticals, medicine, biologics, biotherapeutics and therapeutics for the prevention and treatment of infections or diseases
novosimilar

General Information

Serial Number88048619
Word MarkNOVOSIMILAR
Filing DateMonday, July 23, 2018
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, June 10, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicescells for medical or clinical use; pharmaceuticals, medicines, biologics, biotherapeutics, therapeutics, and biopharmaceutical agents for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejection, inflammatory diseases, and life-threatening diseases; pharmaceutical and biopharmaceutical preparations for the treatment of cancer, infectious diseases, autoimmune disorders, transplant rejection, inflammatory diseases, and life-threatening diseases; pharmaceutical, medical, scientific, and biopharmaceutical research and development; and scientific research in the fields of immunopharmaceuticals, vaccines, pharmaceuticals, medicine, biologics, biotherapeutics and therapeutics for the prevention and treatment of infections or diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 26, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAgenus Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02421

Trademark Events

Event DateEvent Description
Monday, June 10, 2019ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Monday, June 10, 2019ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, November 12, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 12, 2018NON-FINAL ACTION E-MAILED
Monday, November 12, 2018NON-FINAL ACTION WRITTEN
Thursday, November 8, 2018ASSIGNED TO EXAMINER
Thursday, July 26, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM

Related Keywords

novosimilar diseases biopharmaceutical treatment autoimmune rejection transplant life research scientific pharmaceutical